Aprea Therapeutics, Inc. APRE

Aprea Therapeutics announced updated interim results from the Phase 1 ACESOT-1051 study of APR-1051, its oral WEE1 inhibitor, in advanced solid tumors. An abstract with the data has been accepted for an oral plenary presentation at the 38th ENA Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, November 18-20, 2026. Presenting author is Timothy A. Yap of MD Anderson. The trial is registered as NCT06260514. APR-1051 and ATRN-119 are in development for ovarian, colorectal, prostate and breast cancers. Phase 1 interim data presentation could influence early-stage expectations and future trial planning but is unlikely to immediately affect approvals or near-term revenue.

Aprea Therapeutics expands its intellectual property portfolio for precision oncology programs. IP expansion may modestly bolster competitive positioning in oncology but lacks immediate financial or clinical milestones.

Aprea Therapeutics, Inc. (APRE) announced its second quarter 2026 financial results. Quarterly earnings releases deliver performance data that can shift near-term stock price and sentiment.

Aprea Therapeutics, Inc. reported its financial results for the second quarter of 2025, highlighting key developments in its clinical programs. The company provided updates on ongoing trials and emphasized its commitment to advancing its pipeline. Financial metrics showed a focus on managing resources effectively while pursuing strategic goals in drug development. Updates on clinical programs and financial results indicate a moderately noticeable influence on the company's future performance.

Aprea Therapeutics accelerates and expands enrollment in ACESOT-1051 program for WEE1 inhibitor APR-1051, with clinical data presentation planned for Q4 2026. Accelerated APR-1051 enrollment advances clinical development toward 2026 data readout.

Aprea Therapeutics presented updated Phase 1 data on WEE1 inhibitor APR-1051 at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors. Positive Phase 1 data at major oncology conference advances APR-1051 development and strengthens company prospects.

Aprea Therapeutics reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates for biotechs often moderately affect financial performance and investor sentiment.

Aprea Therapeutics to provide clinical update on Phase 1 ACESOT-1051 trial evaluating WEE1 inhibitor APR-1051 at ASCO 2026 Annual Meeting. Phase 1 trial update at ASCO 2026 provides moderate visibility into Aprea's early-stage oncology pipeline and potential investor sentiment.

Aprea Therapeutics, Inc. (APRE) closed an oversubscribed private placement raising $30 million from institutional investors, including Nantahala Capital Management and others, with proceeds funding clinical development of APR-1050 and general corporate purposes. Oversubscribed $30 million private placement delivers critical funding to advance APR-1050 clinical trials and operations, boosting financial runway and investor confidence.

Aprea Therapeutics has dosed a subject with HPV-positive head and neck squamous cell carcinoma in Cohort 5 of the Phase I ACESOT-1051 trial evaluating APR-1051. The trial, conducted at MD Anderson Cancer Center, focuses on monotherapy for advanced solid tumors and will involve 3 to 10 sites. The study aims to assess pharmacokinetics, safety, preliminary efficacy, and pharmacodynamics, with a total of 39 subjects expected to enroll. The trial employs a Bayesian Optimal Interval design for dose levels and will determine the recommended Phase II dose. Open-label data is anticipated later this year, and the company is optimistic about the safety profile of APR-1051. The trial's progress and potential efficacy of APR-1051 could significantly influence Aprea's future performance and market sentiment.

Aprea Therapeutics, Inc. (APRE) announced an oversubscribed $30 million private placement led by existing healthcare-focused institutional investors, with proceeds funding clinical development of APR-1050 and general corporate purposes. Oversubscribed $30 million private placement delivers critical funding for clinical trials and signals robust investor confidence in the company's oncology pipeline.

Aprea Therapeutics highlights positive emerging clinical activity for WEE1 inhibitor APR-1051, including a confirmed partial response in the ongoing Phase 1 ACESOT-1051 trial. Confirmed partial response in Phase 1 trial demonstrates promising early efficacy for APR-1051, likely boosting investor sentiment and accelerating pipeline advancement.

Aprea Therapeutics reported fourth quarter and full year 2025 financial results, highlighting key metrics and cash position, alongside a corporate update on clinical pipeline progress and strategic initiatives. Financial results and corporate updates reveal pipeline advancements and financial health critical to biotech valuation and investor sentiment.

Aprea Therapeutics announces additional positive clinical activity for WEE1 inhibitor APR-1051, including a second partial response in the ongoing ACESOT-1051 trial. Second partial response in APR-1051 trial demonstrates promising efficacy that could accelerate development milestones and boost investor sentiment.

Aprea Therapeutics, Inc. has enhanced its global patent portfolio in the field of DNA Damage Response (DDR) cancer therapeutics, which is expected to support the growth of its pipeline. This strategic move aims to strengthen the company's position in the competitive landscape of cancer treatment. Strengthening the patent portfolio in a critical therapeutic area is likely to significantly impact future growth and market positioning.

Aprea Therapeutics, Inc. has appointed Dr. Eugene Kennedy as Chief Medical Advisor. Dr. Kennedy brings extensive experience in drug development and clinical research, having held leadership roles in various biopharmaceutical companies. His expertise is expected to enhance Aprea's strategic direction and clinical programs, particularly in the development of novel cancer therapies. The appointment of an experienced Chief Medical Advisor may positively influence Aprea's clinical development and strategic initiatives.

Aprea Therapeutics, Inc. announced early clinical proof-of-concept results from its ongoing ACESOT-1051 dose-escalation trial for the WEE1 inhibitor APR-1051. The trial has shown a partial response in a patient observed during the first scan, indicating potential efficacy of the treatment in cancer therapy. The early proof-of-concept results suggest significant potential for APR-1051, which could impact Aprea's market position and investor sentiment.

Aprea Therapeutics, Inc. announced a private placement of $5.6 million priced at-the-market under Nasdaq rules. The offering is expected to provide the company with additional capital to support its ongoing operations and development initiatives. The placement is part of Aprea's strategy to enhance its financial position and advance its clinical programs. The private placement is expected to provide necessary funding for ongoing operations and development, which may moderately influence the company's financial performance.

Aprea Therapeutics, Inc. (APRE) has been identified as a strong sell stock for January 19th, indicating potential concerns regarding its future performance and market position. Investors are advised to reconsider their holdings in light of recent developments that may negatively impact the company's trajectory. Identification as a strong sell stock suggests significant concerns about future performance and market dynamics.

Aprea Therapeutics, Inc. (APRE) has been identified as a strong sell due to its declining stock performance and unfavorable market conditions. Analysts are concerned about the company's financial health and future prospects, leading to a negative outlook for investors. The stock's recent trends indicate significant challenges ahead, prompting recommendations to divest. The negative outlook and strong sell recommendation indicate significant challenges that could alter the company's trajectory and investor sentiment.

Aprea Therapeutics CEO issued a letter to shareholders detailing the company's pipeline advancements in 2025 and outlining expectations for 2026. The letter highlights key developments and strategic initiatives aimed at enhancing the company's market position and driving future growth. Significant advancements in the pipeline and strategic outlook are likely to influence investor sentiment and the company's trajectory.

Aprea Therapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its clinical programs. The company provided updates on ongoing trials and future plans, emphasizing its commitment to advancing therapies in oncology. Financial performance showed trends that may influence investor sentiment and operational strategies moving forward. Updates on clinical programs and financial results may moderately influence Aprea's market performance and investor sentiment.

Aprea Therapeutics, Inc. announced early clinical results from its ACESOT-1051 trial, indicating promising activity for its WEE1 kinase inhibitor, APR-1051. The trial aims to evaluate the safety and efficacy of APR-1051 in patients with advanced solid tumors. Initial data suggests potential therapeutic benefits, which may enhance the company's position in the oncology market. Early signals of activity for APR-1051 could significantly impact Aprea's future performance and investor sentiment.

Aprea Therapeutics, Inc. has established the recommended Phase 2 dose (RP2D) for its investigational drug ATRN-119, which is being evaluated for potential use in combination therapies. This development marks a significant step in the clinical progression of ATRN-119, aimed at enhancing treatment options for patients. Establishing the RP2D for ATRN-119 is a significant milestone that could influence future clinical outcomes and investor sentiment.

Aprea Therapeutics, Inc. announced its participation in the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, where it will present data on its innovative cancer therapies. The presentations are expected to highlight the company's advancements in targeting cancer treatment, showcasing its commitment to addressing unmet medical needs in oncology. This event provides a platform for Aprea to engage with key stakeholders and enhance its visibility in the competitive landscape of cancer therapeutics. Presentations at a significant conference can moderately influence investor sentiment and highlight the company's innovations in cancer treatment.

Aprea Therapeutics announced that initial data from a phase 1 trial of APR-1051 indicated early disease control in patients with HPV-positive head and neck cancer. Early positive trial results for APR-1051 could significantly influence Aprea's market position and investor sentiment.

Aprea Therapeutics, Inc. reported anti-proliferative results and promising early-stage clinical data for its next-generation WEE1 inhibitor, APR-1051, in treating HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC). This development is part of a collaboration with MD Anderson Cancer Center, highlighting the potential of APR-1051 in addressing this specific cancer type. The promising clinical data and collaboration with a leading cancer center indicate a significant potential impact on Aprea's future performance and market position.

Several insiders at Aprea Therapeutics, Inc. (NASDAQ:APRE) have recently purchased shares, indicating confidence in the company's future. The largest purchase was by Independent Director Marc Duey, who bought $132k worth of shares at $4.39 each, despite the current price being $1.64. Over the past year, insiders bought 48.09k shares for $176k while selling 6.46k shares for $30k, suggesting a net positive sentiment. Insiders own 12% of the company, valued at approximately $1.1 million. While recent buying activity is noted, it is not substantial enough to significantly influence investment decisions. Potential risks remain, with three warning signs identified for the company. Insider buying suggests some confidence in the company's value, but the overall impact is limited.

Aprea Therapeutics reported its Q1 2025 financial results, highlighting early anti-tumor activity of ATRN-119 in the ABOYA-119 trial, with tumor shrinkage observed in three patients. The ACESOT-1051 trial for APR-1051 is also progressing, with patients now receiving 100 mg once daily. The company has $19.3 million in cash, sufficient to fund operations into early Q2 2026. Aprea aims to redefine treatment for patients with limited options, with preliminary efficacy data from both trials expected in the second half of 2025. The reported clinical progress and cash position indicate significant potential for future product development and market performance.

Aprea Therapeutics, Inc. has announced the dosing of a patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in its ongoing ACESOT-1051 trial. This trial aims to evaluate the safety and efficacy of the company's investigational therapies in treating this specific cancer type, marking a significant step in their clinical development efforts. The dosing of a patient in a clinical trial indicates progress in product development, which may influence investor sentiment and future performance.